- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 14, 2021
Highlights
- Market Cap
- $30.71M
- Enterprise Value
- $28.79M
- EPS (TTM)
- -$0.34
- EBITDA (TTM)
- -$13.25M
- Year Range
- $0.69 - $3.15
- ROA (TTM)
- -362.33%
- ROE (TTM)
- 251.43%
- Avg. Volume (1M)
- 41K
- Avg. Volume Value (1M)
- $34.41K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ESLA Performance Chart
Estrella Immunopharma Inc. (ESLA) is down 54.3% since the beginning of the year. At $1 per share, ESLA is trading 77.3% below its 52-week high of $3.
Loading charts...
Compare this symbol against anything
Returns By Period
Estrella Immunopharma Inc. (ESLA) has returned -54.25% so far this year and -16.52% over the past 12 months.
Estrella Immunopharma Inc.
- 1D
- -0.89%
- 1M
- -27.36%
- 6M
- -36.28%
- YTD
- -54.25%
- 1Y
- -16.52%
- 3Y*
- -60.00%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -41.63%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ESLA Monthly Returns History
Based on dividend-adjusted daily data since Sep 14, 2021, ESLA's average daily return is +0.07%, while the average monthly return is -0.76%.
Historically, 51% of months were positive and 49% were negative. The best month was Oct 2025 with a return of +110.4%, while the worst month was Oct 2023 at -82.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 3 months.
On a daily basis, ESLA closed higher 35% of trading days. The best single day was Sep 1, 2023 with a return of +191.1%, while the worst single day was Oct 2, 2023 at -62.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -28.21% | 8.93% | -13.11% | 54.72% | -33.54% | -4.59% | -31.38% | -54.25% | |||||
| 2025 | -12.50% | -1.90% | -10.00% | 16.50% | -6.52% | -4.91% | -12.50% | 25.00% | 9.52% | 110.43% | -12.81% | -26.07% | 30.00% |
| 2024 | 0.90% | -8.93% | 21.57% | -15.33% | -9.82% | 10.90% | 48.57% | -19.23% | -7.94% | -31.04% | 41.89% | 5.73% | 8.11% |
| 2023 | 3.69% | 0.56% | -1.40% | 1.04% | 0.28% | 1.12% | -7.10% | -27.51% | 27.95% | -82.87% | 3.75% | -33.13% | -89.21% |
| 2022 | 0.30% | 0.10% | 0.40% | 0.20% | 0.00% | -0.10% | 0.50% | 0.00% | 0.10% | 0.40% | 2.48% | -0.58% | 3.83% |
| 2021 | 0.51% | 0.20% | 0.60% | -0.70% | 0.61% |
Benchmark Metrics
Estrella Immunopharma Inc. has an annualized alpha of 13.74%, beta of 0.31, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 14, 2021.
- This stock participated in 223.69% of S&P 500 Index downside but only 26.47% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.31 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.74%
- Beta
- 0.31
- R²
- 0.00
- Upside Capture
- 26.47%
- Downside Capture
- 223.69%
Return for Risk
Risk / Return Rank
ESLA ranks 42 for risk / return — above 42% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Estrella Immunopharma Inc. (ESLA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ESLA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.55 | ||
| Sortino ratioReturn per unit of downside risk | -1.33 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.25 | -0.18 |
| Calmar ratioReturn relative to maximum drawdown | -0.20 | 2.00 | -2.20 |
| Martin ratioReturn relative to average drawdown | -0.30 | 8.49 | -8.79 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Estrella Immunopharma Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Estrella Immunopharma Inc. was 96.64%, occurring on Jul 31, 2026. The portfolio has not yet recovered.
The current Estrella Immunopharma Inc. drawdown is 96.64%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-96.64%Jul 2026 | 2y 11mo | — | 2y 11moSep 2023 - now | — |
-35.78%Aug 2023 | 26d | 4d | 1moAug 2023 - Sep 2023 | — |
-9.91%Jul 2023 | 8d | 6d | 14dJul 2023 - Aug 2023 | — |
-4.95%Jun 2022 | 1mo 2d | 7mo 7d | 8mo 9dMay 2022 - Jan 2023 | Bear market2022 |
-4.36%May 2023 | 6d | 1mo 22d | 1mo 28dMay 2023 - Jul 2023 | — |
Drawdown Indicators
| ESLA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.64% | -56.78% | -39.86% |
Max Drawdown (1Y)Largest decline over 1 year | -76.60% | -9.10% | -67.50% |
Max Drawdown (3Y)Largest decline over 3 years | -96.64% | -18.90% | -77.74% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -96.64% | -1.58% | -95.06% |
Average DrawdownAverage peak-to-trough decline | -56.67% | -10.70% | -45.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 49.82% | 2.14% | +47.68% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Estrella Immunopharma Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Estrella Immunopharma Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ESLA
Add Estrella Immunopharma Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ESLA